Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075534 Target Snapshot

NCI-H2170 · CELL-LINE · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
172Compounds
30Assays
23Approved Drugs
117.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NCI-H2170 as ChEMBL target CHEMBL1075534. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NCI-H2170
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1075534
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NCI-H2170 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNCI-H2170
Target TypeCELL-LINE
OrganismHomo sapiens
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNCI-H2170
UniProt AccessionN/A

NCI-H2170

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as NCI-H2170.

Review nameNCI-H2170
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

23
Approved
10
Phase III
11
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50117.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL105 9.82 IC50 0.1513 Approved
CHEMBL94657 8.28 IC50 5.217 Clinical
CHEMBL3545252 8.27 IC50 5.348 Approved
CHEMBL3128043 8.22 IC50 6.04 Preclinical
CHEMBL553025 7.94 IC50 11.6 Approved
CHEMBL888 7.92 IC50 11.97 Approved
CHEMBL65 7.86 IC50 13.71 Preclinical
CHEMBL96926 7.84 IC50 14.4 Preclinical
CHEMBL1738758 7.82 IC50 15.0 Clinical
CHEMBL1972860 7.54 IC50 28.85 Clinical
Distribution

pChEMBL Value Distribution

12
5.0
15
5.5
6
6.0
5
6.5
3
7.0
6
7.5
3
8.0
0
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
AFATINIB
CHEMBL1173655
Approved 2013
Properties Compare Identifier
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
Properties Compare Identifier
GEMCITABINE
CHEMBL888
Approved 1996
Properties Compare Identifier
DOCETAXEL
CHEMBL3545252
Approved 1995
Properties Compare Identifier
VINORELBINE
CHEMBL553025
Approved 1994
Properties Compare Identifier
MITOMYCIN
CHEMBL105
Approved 1981
Properties Compare Identifier
DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
VINBLASTINE
CHEMBL159
Approved 1965
Properties Compare Identifier
Assay Landscape

Assay Landscape

30
Total Assays
114
Tested Compounds
1
Assay Types
Functional — 30 assays, 114 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 30 114 5.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine